)
Edge1 May 2026
Making the Marlboro Man
The story of Marlboro's transformation from a women's cigarette to a global icon: one of the most effective brand repositionings in history.
Transgene
Transgene (TNG) investor relations material
Transgene Q1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2026 earnings summary29 Apr, 2026
Executive summary
Enrollment completed for Phase 2 of TG4050 trial in head and neck cancer; topline data expected by end of Q1 2028.
Phase 1 data published, showing robust immune responses and all patients disease-free at 2 years.
License agreement signed with NEC Bio to advance TG4050 clinical development and commercialization.
Financial visibility secured until early 2028.
Financial highlights
Q1 2026 operating revenue was €1.4 million, down from €2.5 million in Q1 2025, mainly due to lower research tax credit.
Cash, cash equivalents, and financial assets totaled €103.8 million as of March 31, 2026, compared to €111.9 million at year-end 2025.
Net cash burn for Q1 2026 was €8.1 million, improved from €14.8 million in Q1 2025.
Outlook and guidance
Topline results for the Phase 2 TG4050 trial expected by end of Q1 2028.
3-year disease-free survival follow-up for Phase 1 patients anticipated in Q2/Q3 2026.
Plans to initiate a new Phase 1 trial in a second indication later in 2026.
Timing for TG4050 Phase 1 3-year DFS results
NEC Bio license agreement payment structure
Planned start for the second myvac indication
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Transgene
- TG4050 achieved 100% 2-year DFS in Phase 1 HNSCC; funding secured to early 2028.TNG
H2 20259 May 2026 - TG4050 shows all patients disease-free at 18.6 months; financial runway secured to Q4 2025.TNGH1 202420 Jan 2026
- TG4001 plus avelumab missed its main goal but showed promise in cervical cancer patients.TNGStudy Update19 Jan 2026
- TG4050 achieved 24.1-month disease-free results; funding secured through April 2026.TNGH2 202427 Dec 2025
- TG4050 achieved 100% 2-year DFS in Phase I, with funding and leadership secured through 2026.TNGH1 202514 Dec 2025
- TG4050 achieved 100% disease-free survival at 24 months with durable, specific T cell responses.TNGStatus Update14 Nov 2025
- TG4050 achieved 100% 30-month disease-free survival with durable immune response.TNGStatus Update13 Nov 2025
- TG4050 and BT-001 deliver promising clinical results as funding supports growth through 2026.TNGQ3 20254 Nov 2025
- TG4050 achieved 100% 2-year disease-free survival in head and neck cancer Phase I trial.TNGCorporate Presentation4 Jul 2025
Next Transgene earnings date
AGM 202622 May, 2026
Transgene
Next Transgene earnings date
AGM 202622 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage